1. Search Result
Search Result
Isoforms Recommended: MetAP2
Results for "

MetAP2

" in MedChemExpress (MCE) Product Catalog:

33

Inhibitors & Agonists

1

Peptides

3

Recombinant Proteins

2

Antibodies

3

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-128147

    MetAP Metabolic Disease Cancer
    MetAP-2-IN-6 (4-(4-bromophenyl)-1H-1,2,3-triazole) is a MetAP2 inhibitor. MetAP-2-IN-6 can be used for research in conditions mediated by angiogenesis .
    MetAP-2-IN-6
  • HY-120868
    TP-004
    1 Publications Verification

    MetAP Metabolic Disease Cancer
    TP-004 is a potent and reversible inhibitor of methionine aminopeptidase 2 (MetAP2), with an IC50 of 6 nM against MetAP2. TP-004 is a chemical probe. TP-004 suppresses MetAP2 enzymatic activity, blocks N-terminal methionine cleavage, impairs protein maturation and stability, and thereby inhibits cell proliferation and angiogenesis. TP-004 can be used for the study of tumors and diseases associated with excessive angiogenesis .
    TP-004
  • HY-P4344

    MetAP Others
    Met-Gly-Pro-AMC is a fluorescent peptide substrate of MetAP2 .
    Met-Gly-Pro-AMC
  • HY-133016

    MetAP Cardiovascular Disease Cancer
    M8891 is an orally active, reversible and brain penetrant Methionine Aminopeptidase-2 (MetAP-2) inhibitor with an IC50 of 54 nM and a Ki of 4.33 nM. M8891 does not inhibit MetAP-1 (IC50>10 µM) . M8891 inhibits growth of primary endothelial cells as well as tumor cells and demonstrates antiangiogenic and antitumoral activity [2].
    M8891
  • HY-114196

    ZGN-1061

    MetAP Metabolic Disease
    Aclimostat (ZGN-1061) is a potent inhibitor of the MetAP2 enzyme and displays favorable efficacy and safety in preclinical studies. ZGN-1061 produced similar efficacy as beloranib for weight loss, improvements in metabolic parameters in a mouse model of obesity and insulin resistance, and concordant changes in gene transcription in HepG2 cells .
    Aclimostat
  • HY-13731

    MetAP Inflammation/Immunology Cancer
    PPI-2458 is a potent, orally active, selective and irreversible inhibitor of methionine aminopeptidase-2 (MetAP-2). PPI-2458 can be used for arthritis and lymphoma research [2].
    PPI-2458
  • HY-14811

    ZGN-440; CKD-732 free base

    MetAP NF-κB Metabolic Disease
    Beloranib (ZGN-440; CKD-732 free base) is a selective, irreversible inhibitor of methionine aminopeptidase MetAP2 that suppresses appetite and increases energy expenditure. Beloranib blocks the enzymatic cleavage of N-terminal methionine from nascent proteins by forming a covalent bond with MetAP2, thereby regulating fatty acid metabolism, adrenergic signaling, and hypothalamic NF-κB expression. Beloranib significantly reduces food intake, body weight, and fat accumulation, while improving glucose tolerance, insulin sensitivity, and lipid metabolism. Beloranib also elevates energy expenditure and fat oxidation levels, without affecting body temperature, spontaneous activity, or the inflammatory cytokine IL-1β. Beloranib can be used in research on obesity and hypothalamic obesity [2] .
    Beloranib
  • HY-161743

    AUTOTACs Autophagy Neurological Disease Cancer
    PBA-1105 is an autophagy-targeting chimera (AUTOTAC) that induces p62 self-oligomerization. PBA-1105 selectively binds to exposed hydrophobic regions of misfolded proteins, facilitating their degradation via the autophagic pathway. PBA-1105 increases the autophagic flux of Ub-conjugated aggregates .
    PBA-1105
  • HY-168967

    MetAP Cancer
    BAY-277, a chemical probe, is a METAP2 degrader, with IC50 values of 5.8 nM and 5.9 nM for hMETAP2 and mMETAP2, respectively .
    BAY-277
  • HY-RS08350

    Small Interfering RNA (siRNA) Others

    METAP2 Human Pre-designed siRNA Set A contains three designed siRNAs for METAP2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    METAP2 Human Pre-designed siRNA Set A
    METAP2 Human Pre-designed siRNA Set A
  • HY-156959

    JAK TRP Channel MetAP Infection Inflammation/Immunology
    Ovalicin is a multi-target inhibitor that targets MetAP2, HRH2, JAK2 and TRPV1, with anti-inflammatory and anti-atopic dermatitis activities. Ovalicin covalently binds to MetAP2 to inhibit its function, thereby blocking the replication of Enterocytozoon bieneusi and Vittaforma corneae. Ovalicin alleviates intestinal injury and prolongs survival in infected mouse models, without showing obvious hepatorenal toxicity. Ovalicin attenuates LPS-induced calcium influx, reduces the infiltration of macrophages and mast cells in the skin, and regulates the expression of inflammation-related genes such as IL-31, effectively relieving allergic symptoms in mouse models. Ovalicin can be used for the research of microsporidiosis and atopic dermatitis [2].
    Ovalicin
  • HY-161742

    AUTOTACs MetAP Autophagy p62 Cancer
    Fumagilin-105 is an autophagy-targeting chimera (AUTOTAC) that degrades MetAP2 via p62-mediated macroautophagy in a ubiquitination-independent manner. Fumagilin-105 can inhibit the migration of tumor cells and induce programmed cell death. Fumagilin-105 has anti-tumor activity. (p62-ZZ ligand (HY-W489121); target-binding ligand (HY-B0751); linker (HY-W245803)) .
    Fumagilin-105
  • HY-119062

    MetAP CDK Cancer
    A-800141 is an orally active, selective, sulfonamide-based MetAP2 inhibitor (IC50=12 nM) that binds reversibly to MetAP2 and interacts with its manganese ions. A-800141 induces the production of N-terminal methionine-unprocessed GAPDH variants, which in turn triggers G1-phase cell cycle arrest, elevates p21 levels, and reduces the levels of phosphorylated Rb and total cyclin A. A-800141 exhibits anti-angiogenic and tumor growth inhibitory effects, and produces synergistic effects when combined with cytotoxic inhibitors or BCL-2 inhibitors. A-800141 has been widely used in scientific research related to B-cell lymphoma, neuroblastoma, prostate cancer, colon cancer, melanoma and other fields [2] .
    A-800141
  • HY-118953

    MetAP Cancer
    LAF389, a benaamide B analogue, is a methionine aminopeptidases (MetAps) inhibitor with an IC50 of 800 nM for MetAp2. LAF389 has both antiproliferative and antiangiogenetic properties and can inhibit tumor cells growth. LAF389 can be used for the research of cancer [2].
    LAF389
  • HY-134183

    AUTACs Autophagy Metabolic Disease Cancer
    AUTAC1 is a MetAP2-targeting autophagy-mediated degrader (AUTAC). AUTACs contain a degradation tag and a warhead to provide target specificity. AUTAC1 contains an FBnG (p-Fluorobenzyl Guanine) and a Fumagillol moiety. Fumagillol binds covalently to MetAP2 .
    AUTAC1
  • HY-133016A

    MetAP Others
    (R)-M8891 (compound R-9) is a less active isomer of M8891. M8891 is an orally active, reversible and brain penetrant Methionine Aminopeptidase-2 (MetAP-2) inhibitor .
    (R)-M8891
  • HY-109188

    MetAP Metabolic Disease
    Relzomostat is a methionine aminopeptidase 2 (MetAP2) inhibitor.Relzomostat may be useful for the research of obesity, type 2 diabetes, and other obesity-associated conditions .
    Relzomostat
  • HY-14811A

    ZGN-440 hemioxalate; ZGN-433 hemioxalate; CDK732 hemioxalate

    NF-κB MetAP Metabolic Disease
    Beloranib (ZGN-440; CKD-732 free base) hemioxalate is a selective, irreversible inhibitor of methionine aminopeptidase MetAP2 that suppresses appetite and increases energy expenditure. Beloranib hemioxalate blocks the enzymatic cleavage of N-terminal methionine from nascent proteins by forming a covalent bond with MetAP2, thereby regulating fatty acid metabolism, adrenergic signaling, and hypothalamic NF-κB expression. Beloranib hemioxalate significantly reduces food intake, body weight, and fat accumulation, while improving glucose tolerance, insulin sensitivity, and lipid metabolism. Beloranib hemioxalate also elevates energy expenditure and fat oxidation levels, without affecting body temperature, spontaneous activity, or the inflammatory cytokine IL-1β. Beloranib hemioxalate can be used in research on obesity and hypothalamic obesity [2] .
    Beloranib hemioxalate
  • HY-158006

    MetAP Cancer
    SDX-7539 is a selective inhibitor for Methionine aminopeptidase type 2 (MetAP2). SDX-7539 inhibits proliferarion of HUVECs with an IC50 of 120 μM. SDX-7539 exhibits antitumor activity in NSCLC xenograft athymic nude mice .
    SDX-7539
  • HY-103653

    MetAP Cardiovascular Disease Cancer
    CKD-731 is a Fumagillin (HY-B0751) analogue. CKD-731 inhibits the proliferation of calf pulmonary artery endothelial cells (CPAE), lymphoma EL-4 cells and murine leukemia P388D1 cells. CKD-731 exerts the effect of inhibiting MetAP-2 activity and blocking angiogenesis. CKD-731 can be used for the research of anti-angiogenesis-related cancer .
    CKD-731
  • HY-150409

    TSPO Cancer
    TSPO ligand-2 is a ligand of AUTAC1. AUTAC1 contains an p-fluorobenzylguanine (FBnG) and a Fumagillol moiety, which can silence endogenous MetAP2 in HeLa cells .
    TSPO ligand-2
  • HY-116861

    MetAP Cancer
    A-357300 is a reversible and selective MetAP2 inhibitor with IC50s of 0.12 and 57 μM against MetAP2 and MetAP1. A-357300 induces cytostasis by cell cycle arrest at the G1 phase selectively in endothelial cells and in a subset of tumor cells. A-357300 inhibits angiogenesis both in vitro and in vivo and shows potent antitumor efficacy in carcinoma, sarcoma, and neuroblastoma murine models. A-357300 can be used for the studies of neuroblastoma, fibrosarcoma and breast cancer .
    A-357300
  • HY-161745

    AUTOTACs p62 Autophagy Cancer
    PBA-1105b is an autophagy-targeting chimera (AUTOTAC) that induces p62 self-oligomerization. PBA-1105b increases the autophagic flux of Ub-conjugated aggregates. PBA-1105b is a drastically longer PEG-based linker than PBA-1105 .
    PBA-1105b
  • HY-RS24322

    Small Interfering RNA (siRNA) Others

    Metap2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Metap2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Metap2 Rat Pre-designed siRNA Set A
    Metap2 Rat Pre-designed siRNA Set A
  • HY-RS17853

    Small Interfering RNA (siRNA) Others

    Metap2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Metap2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Metap2 Mouse Pre-designed siRNA Set A
    Metap2 Mouse Pre-designed siRNA Set A
  • HY-161744

    AUTOTACs Autophagy Cancer
    PBA-1106 is an autophagy-targeting chimera (AUTOTAC) that induces p62 self-oligomerization. PBA-1106 increases the autophagic flux of Ub-conjugated aggregates .
    PBA-1106
  • HY-181643

    MetAP Infection
    YOK24 is an orally active MetAP2 inhibitor and anti-amoebic agent. YOK24 binds covalently to MetAP2 and inhibits its peptidase activity, where MetAP2 is a protein essential for the proliferation of *Entamoeba histolytica*. YOK24 can be used in the research of amoebiasis .
    YOK24
  • HY-182419

    MetAP Cancer
    A-849519 is a reversible methionine aminopeptidase-2 (MetAP-2) inhibitor with an IC50 of 19 nM. A-849519 binds to the active site of the Mn 2+ form of human MetAP-2, where the oxygen atom of one acidic functional group interacts with the manganese ion, and another heteroatom binds to the water molecule above the two manganese ions, thereby functionally inhibiting enzyme activity. A-849519 inhibits the methionine processing activity of MetAP-2 as well as the proliferation of fibrosarcoma cells. A-849519 can be used in studies related to fibrosarcoma [2].
    A-849519
  • HY-182482

    MetAP Cancer
    SB-587094 is a MetAP-2 inhibitor. SB-587094 inhibits cobalt- and manganese-containing hMetAP2. SB-587094 inhibits endothelial cell proliferation. SB-587094 is applicable to cancer-related research [2].
    SB-587094
  • HY-182781

    MetAP Cancer
    Anticancer agent 313 is a MetAP2 inhibitor with an IC50 of 4.11 μM. Anticancer agent 313 activates the transcription factor ATF4 via a non-canonical mTORC1-dependent pathway. Anticancer agent 313 inhibits cancer cell proliferation. Anticancer agent 313 is applicable to the research of breast cancer and pancreatic cancer .
    Anticancer agent 313
  • HY-122225

    MetAP Cancer
    JNJ-4929821 (Compound 88), a triazole derivative, is a selective Methionine aminopeptidase-2 (MetAP-2) inhibitor with an IC50 of 15  nM over MetAP-1. JNJ-4929821 can be used for cancers like liver cancer, colorectal adenocarcinoma and pancreatic cancer research .
    JNJ-4929821
  • HY-133806

    MetAP VEGFR Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
    Fumarranol, a Fumagillin (HY-B0751) analogue, is a selective type 2 methionine aminopeptidase (MetAP2) inhibitor with a human IC50 of 3.2 μM. Fumarranol inhibits proliferation of bovine aortic endothelial cells and inhibits angiogenesis in a mouse matrigel plug model. Fumarranol can be used for the researches of cancer, diabetic retinopathy, age-related macular degeneration .
    Fumarranol
  • HY-181644

    MetAP Infection
    NS-181 is a MetAP2 inhibitor and antiamebic agent with oral effectiveness.NS-181 functionally inhibits methionine aminopeptidase 2, a protein critical for Entamoeba histolytica proliferation. NS-181 exerts antiamebic activity against Entamoeba histolytica, leading to resolution of amebic liver abscess. NS-181 can be used for the research of amebiasis .
    NS-181

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: